warning icon

COVID-19 DEW Report, powered by Reformulary®Read more


‘Very Soon’ says Johnson & Johnson CEO as world waits for its COVID-19 vaccine data

Johnson & Johnson is moving close to releasing efficacy data from Phase 3 trials of its COVID-19 vaccine candidate. Strong data and regulatory approval would represent a major step in countries’ vaccination efforts, as unlike other COVID-19 vaccines currently in use the J&J vaccine is administered as a single dose.

Published: January 12, 2021


Read Article